{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T20:52:47Z","timestamp":1793134367838,"version":"4.5.0"},"reference-count":50,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,4,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Essential thrombocythemia (ET) is characterized by enhanced platelet generation and thrombotic complications. Once-daily low-dose aspirin incompletely inhibits platelet thromboxane A2 (TXA2) in the majority of ET patients. In the present study, we investigated the determinants of aspirin-insensitive platelet TXA2 biosynthesis and whether it could be further suppressed by changing the aspirin dose, formulation, or dosing interval. In 41 aspirin-treated ET patients, the immature platelet count predicted serum TXB2 independently of platelet count, age, JAK-2 V617F mutation, or cytoreduction (\u03b2 = 3.53, P = .001). Twenty-one aspirin-treated patients with serum TXB2 \u2265 4 ng\/mL at 24 hours after dosing were randomized to the following 7-day regimens in a crossover design: enteric-coated aspirin 100 mg twice daily, enteric-coated aspirin 200 mg once daily, or plain aspirin 100 mg once daily. A twice-daily regimen caused a further 88% median (IQR, 78%-92%, P &lt; .001) TXB2 reduction and normalized the functional platelet response to aspirin, as assessed by urinary 11-dehydro-TXB2 excretion and the VerifyNow Aspirin assay. Doubling the aspirin dose reduced serum TXB2 only partially by 39% median (IQR, 29%-54%, P &lt; .05). We conclude that the abnormal megakaryopoiesis characterizing ET accounts for a shorter-lasting antiplatelet effect of low-dose aspirin through faster renewal of platelet cyclooxygenase-1, and impaired platelet inhibition can be rescued by modulating the aspirin dosing interval rather than the dose.<\/jats:p>","DOI":"10.1182\/blood-2011-06-359224","type":"journal-article","created":{"date-parts":[[2012,1,11]],"date-time":"2012-01-11T01:21:56Z","timestamp":1326244916000},"page":"3595-3603","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":190,"title":["Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target"],"prefix":"10.1182","volume":"119","author":[{"given":"Silvia","family":"Pascale","sequence":"first","affiliation":[{"name":"Department of Hematology, Spirito Santo Hospital, Pescara, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Petrucci","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Catholic University School of Medicine, Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Dragani","sequence":"additional","affiliation":[{"name":"Department of Hematology, Spirito Santo Hospital, Pescara, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aida","family":"Habib","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, American University of Beirut, Beirut, Lebanon;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Zaccardi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Catholic University School of Medicine, Rome, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Pagliaccia","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Catholic University School of Medicine, Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Pocaterra","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Catholic University School of Medicine, Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enzo","family":"Ragazzoni","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Catholic University School of Medicine, Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Rolandi","sequence":"additional","affiliation":[{"name":"Hemostasis and Thrombosis Laboratory, Spirito Santo Hospital, Pescara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Rocca","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Catholic University School of Medicine, Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Patrono","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Catholic University School of Medicine, Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"5","key":"2019111821440334100_B1","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/ajh.21129","article-title":"Prevalence of polycythemia vera and essential thrombocythemia.","volume":"83","author":"Ma","year":"2008","journal-title":"Am J Hematol"},{"issue":"5","key":"2019111821440334100_B2","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1200\/JCO.2010.29.8711","article-title":"Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies.","volume":"29","author":"Tefferi","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111821440334100_B3","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.bcmd.2005.12.031","article-title":"Thrombotic complications in essential thrombocythemia (ET): clinical facts and biochemical riddles.","volume":"36","author":"Petrides","year":"2006","journal-title":"Blood Cells Mol Dis"},{"issue":"5","key":"2019111821440334100_B4","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1182\/blood-2010-08-270033","article-title":"How I treat essential thrombocythemia.","volume":"117","author":"Beer","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2019111821440334100_B5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00277-008-0531-7","article-title":"Long term management of thrombocytosis in essential thrombocythemia.","volume":"88","author":"Birgeg\u00e5rd","year":"2009","journal-title":"Ann Hematol"},{"issue":"11","key":"2019111821440334100_B6","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.3324\/haematol.13346","article-title":"Prognostic factors for thrombosis, myelofibrosis and leukaemia in essential thrombocythemia: a study of 605 patients.","volume":"93","author":"Passamonti","year":"2008","journal-title":"Haematologica"},{"issue":"2","key":"2019111821440334100_B7","first-page":"CD006503","article-title":"Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia.","author":"Squizzato","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"22","key":"2019111821440334100_B8","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","article-title":"Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients.","volume":"117","author":"Carobbio","year":"2011","journal-title":"Blood"},{"issue":"17","key":"2019111821440334100_B9","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJM199504273321704","article-title":"Hydroxyurea for patients with essential thrombocythemia at high risk of thrombosis.","volume":"332","author":"Cortelazzo","year":"1995","journal-title":"New Engl J Med"},{"issue":"1","key":"2019111821440334100_B10","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.","volume":"353","author":"Harrison","year":"2005","journal-title":"N Engl J Med"},{"issue":"3","key":"2019111821440334100_B11","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3324\/haematol.12053","article-title":"Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors and effect of treatments.","volume":"93","author":"De Stefano","year":"2008","journal-title":"Haematologica"},{"key":"2019111821440334100_B12","article-title":"Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria [published online ahead of print September 16, 2011].","author":"Finazzi","journal-title":"Leukemia"},{"issue":"7","key":"2019111821440334100_B13","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1182\/blood.V99.7.2612","article-title":"Increased soluble and platelet-associated CD40 ligand in essential thrombocythemia and reactive thrombocytosis.","volume":"99","author":"Viallard","year":"2002","journal-title":"Blood"},{"issue":"2","key":"2019111821440334100_B14","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/ajh.21338","article-title":"Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK-2 V617F allele burden.","volume":"84","author":"Arellano-Rodrigo","year":"2009","journal-title":"Am J Hematol"},{"issue":"5","key":"2019111821440334100_B15","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1055\/s-0038-1649916","article-title":"Increased thromboxane biosynthesis in essential thrombocythemia.","volume":"74","author":"Rocca","year":"1995","journal-title":"Thromb Haemost"},{"issue":"5","key":"2019111821440334100_B16","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1182\/blood-2009-08-236679","article-title":"The contribution of cyclooxygenase-1 and cyclooxygenase-2 to aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia: implications for antiplatelet therapy.","volume":"115","author":"Dragani","year":"2010","journal-title":"Blood"},{"issue":"24","key":"2019111821440334100_B17","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMra071014","article-title":"Platelet activation and atherothrombosis.","volume":"357","author":"Dav\u00ec","year":"2007","journal-title":"N Engl J Med"},{"issue":"2","key":"2019111821440334100_B18","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera.","volume":"350","author":"Landolfi","year":"2004","journal-title":"N Engl J Med"},{"issue":"22","key":"2019111821440334100_B19","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1056\/NEJMra052717","article-title":"Low-dose aspirin for the prevention of atherothrombosis.","volume":"353","author":"Patrono","year":"2005","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111821440334100_B20","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1172\/JCI110576","article-title":"Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects.","volume":"69","author":"Patrignani","year":"1982","journal-title":"J Clin Invest"},{"issue":"8","key":"2019111821440334100_B21","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jacc.2008.10.047","article-title":"Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin \u201cresistance.\u201d","volume":"53","author":"Santilli","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"2019111821440334100_B22","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/00001721-199206000-00006","article-title":"Increased hydrogen peroxide formation in platelets of patients affected with essential thrombocythaemia (ET).","volume":"3","author":"Leoncini","year":"1992","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"1","key":"2019111821440334100_B23","first-page":"26","article-title":"Increased neutrophil respiratory burst in myeloproliferative disorders: selective enhancement of superoxide release triggered by receptor-mediated agonists and low responsiveness to in vitro cytokine stimulation.","volume":"25","author":"Iki","year":"1997","journal-title":"Exp Hematol"},{"issue":"7","key":"2019111821440334100_B24","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.bcp.2007.12.005","article-title":"Acetylation of prostaglandin H2 synthase by aspirin is inhibited by redox cycling of the peroxidase.","volume":"75","author":"Bala","year":"2008","journal-title":"Biochem Pharmacol"},{"key":"2019111821440334100_B25","article-title":"International Agency for Research on Cancer.","author":"Swerdlow","year":"2008","journal-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue"},{"key":"2019111821440334100_B26","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.2337\/dc10-S062","article-title":"Diagnosis and classification of diabetes mellitus.","volume":"33","author":"American Diabetes Association","year":"2010","journal-title":"Diabetes Care"},{"issue":"6","key":"2019111821440334100_B27","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1046\/j.1365-2257.2000.00330.x","article-title":"New quantitative parameters on a recently introduced automated blood cell counter \u2013 the XE-2100.","volume":"22","author":"Briggs","year":"2000","journal-title":"Clin Lab Haematol"},{"issue":"17","key":"2019111821440334100_B28","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1056\/NEJM198710223171701","article-title":"Plasma glycocalicin. An aid in the classification of thrombocytopenic disorders.","volume":"317","author":"Steinberg","year":"1987","journal-title":"N Engl J Med"},{"issue":"3","key":"2019111821440334100_B29","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1182\/blood.V83.3.691.691","article-title":"Glycocalicin: a new assay-the normal plasma levels and its potential usefulness in selected diseases.","volume":"83","author":"Beer","year":"1994","journal-title":"Blood"},{"issue":"3-4","key":"2019111821440334100_B30","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0049-3848(80)90066-3","article-title":"Low-dose aspirin and inhibition of thromboxane B2 production in healthy subjects.","volume":"17","author":"Patrono","year":"1980","journal-title":"Thromb Res"},{"issue":"7","key":"2019111821440334100_B31","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1021\/ac00284a003","article-title":"Enzyme immunoassays of eicosanoids using acetylcholine esterase as label: an alternative to radioimmunoassay.","volume":"57","author":"Pradelles","year":"1985","journal-title":"Anal Chem"},{"key":"2019111821440334100_B32","first-page":"187","article-title":"Radioimmunoassay of serum thromboxane B2: a simple method of assessing pharmacologic effects on platelet function.","volume":"6","author":"Patrono","year":"1980","journal-title":"Adv Prostaglandin Thromboxane Res"},{"issue":"11","key":"2019111821440334100_B33","doi-asserted-by":"crossref","first-page":"7634","DOI":"10.1073\/pnas.112202999","article-title":"Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets.","volume":"99","author":"Rocca","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2019111821440334100_B34","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S0022-3565(25)12087-9","article-title":"Immunological characterization of urinary 8-epi-prostaglandin F2 alpha excretion in man.","volume":"275","author":"Wang","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"2019111821440334100_B35","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0005-2760(87)90233-5","article-title":"Radioimmunoassay of 11-dehydro-thromboxane B2 in human plasma and urine.","volume":"918","author":"Ciabattoni","year":"1987","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"2019111821440334100_B36","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3324\/haematol.2010.031070","article-title":"Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3.","volume":"96","author":"Barbui","year":"2011","journal-title":"Haematologica"},{"issue":"9","key":"2019111821440334100_B37","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1182\/blood-2011-02-339655","article-title":"JAK-2 V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients.","volume":"118","author":"Panova-Noeva","year":"2011","journal-title":"Blood"},{"issue":"11","key":"2019111821440334100_B38","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1161\/01.ATV.17.11.2309","article-title":"Isoprostanes: potential markers of oxidant stress in atherothrombotic disease.","volume":"17","author":"Patrono","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2019111821440334100_B39","doi-asserted-by":"crossref","first-page":"199S","DOI":"10.1378\/chest.08-0672","article-title":"Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Ed).","volume":"133","author":"Patrono","year":"2008","journal-title":"Chest"},{"issue":"8","key":"2019111821440334100_B40","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/nsb0895-637","article-title":"The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase.","volume":"2","author":"Loll","year":"1995","journal-title":"Nat Struct Biol"},{"key":"2019111821440334100_B41","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1172\/JCI108941","article-title":"Inhibition of platelet prostaglandin synthetase by oral aspirin.","volume":"61","author":"Burch","year":"1978","journal-title":"J Clin Invest"},{"issue":"6","key":"2019111821440334100_B42","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1161\/01.CIR.72.6.1177","article-title":"Clinical pharmacology of platelet cyclooxygenase inhibition.","volume":"72","author":"Patrono","year":"1985","journal-title":"Circulation"},{"issue":"19","key":"2019111821440334100_B43","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJM198411083111902","article-title":"Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase.","volume":"311","author":"Pedersen","year":"1984","journal-title":"N Engl J Med"},{"issue":"25","key":"2019111821440334100_B44","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1161\/CIRCULATIONAHA.109.900589","article-title":"Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization.","volume":"120","author":"Frelinger","year":"2009","journal-title":"Circulation"},{"issue":"8","key":"2019111821440334100_B45","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1161\/01.STR.0000231683.43347.ec","article-title":"Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers.","volume":"37","author":"Cox","year":"2006","journal-title":"Stroke"},{"issue":"8","key":"2019111821440334100_B46","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.jcin.2010.05.014","article-title":"Patients with previous definite stent thrombosis have a reduced antiplatelet effect of aspirin and a larger fraction of immature platelets.","volume":"3","author":"W\u00fcrtz","year":"2010","journal-title":"JACC Cardiovasc Interv"},{"issue":"3","key":"2019111821440334100_B47","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1538-7836.2007.02387.x","article-title":"Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin.","volume":"5","author":"Guthikonda","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2019111821440334100_B48","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ahj.2006.10.040","article-title":"Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review.","volume":"153","author":"Hovens","year":"2007","journal-title":"Am Heart J"},{"issue":"12","key":"2019111821440334100_B49","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.jacc.2010.04.047","article-title":"Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.","volume":"56","author":"Bonello","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2019111821440334100_B50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-510X(96)00308-5","article-title":"European Stroke Prevention Study: II. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke.","volume":"143","author":"Diener","year":"1996","journal-title":"J Neurol Sci"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/15\/3595\/1497657\/zh801512003595.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/15\/3595\/1497657\/zh801512003595.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T18:18:56Z","timestamp":1742321936000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/119\/15\/3595\/105568\/Aspirininsensitive-thromboxane-biosynthesis-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,12]]},"references-count":50,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2012,4,12]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-06-359224","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,12]]}}}